Objective: To describe the profile of joint mobility and grip and pinch strength of MPS VI patients and to correlate this with urinary excretion of glycosaminoglycans (GAGs), ARSB activity, and the distance covered in a 6-minute walking test (6MWT).
Introduction
The mucopolysaccharidoses (MPS) are a group of lysosomal diseases caused by a deficiency of one of the enzymes involved in catabolism of glycosaminoglycans (GAGs), which are macromolecules found in the extracellular space and cell membrane. The global incidence of MPS is estimated at 1.3-4.5:100,000 births. [1] [2] [3] This group of diseases is classified according to which enzyme is deficient (Table 1) . Although each type of MPS exhibits a highly heterogeneous phenotype, symptoms usuallys start in childhood) 2 and patients exhibit hepatosplenomegaly and cardiac, respiratory, ocular, bone and joint involvement (neurological compromise is variable). Studies undertaken with MPS Brazilian patients suggest both that there is an underdiagnosis of MPS and that the mean age of diagnosis is higher in our country, which prevent families' early access to genetic counseling and specific treatment. [4] [5] [6] MPS type VI (MPS VI) was described for the first time in 1963 and is a type of MPS that is clinically similar to MPS I, but with intelligence preserved and increased urinary excretion of the GAG dermatan sulphate (DS) ( Table 1) . 2, 7 It is an autosomal recessive disease, caused by a deficiency in the activ-ity of the lysosomal hydrolase N-acetylgalactosamine 4-sulfatase, or arylsulfatase B (ARSB), coded by the ARSB gene which is located on chromosome 5q13-14. 5 It would appear that MPS VI is one of the rarest types of MPS, 1,3 but in Brazil this situation is different, since here this is one of the most often diagnosed types of MPS. 8, 9 The causes of this finding are not yet known. Patients with MPS VI usually appear normal at birth, but occasionally may present characteristics such as dolicocephaly, wide forehead and spinal abnormalities. As the disease progresses, and depending on the severity of the case, they will develop abnormalities in a range of different organs and tissues. These may include facial infiltration, hepatosplenomegaly, growth deficit, joint contractures, cardiovascular involvement, ocular abnormalities (corneal clouding, glaucoma and papilledema with optical atrophy), neurological involvement (hydrocephalus, medullar compression; mental retardation is not a common occurrence), obstructive sleep apnea syndrome and umbilical and inguinal hernias. 2 Osteoarticular manifestations, which are the subject of this study, are generally secondary to metaphyseal involvement and thickening and fibrosis of the articular capsule. 10 They are progressive changes that limit movements, 7 and in some joints, especially knees, hips and elbows, limitations are present from the first years of life onwards. 2, 7 Flexional contractures in the fingers give them a claw-like appearance 2 ( Figure 1 ). The emergence of carpal tunnel syndrome, due to compression of the median nerve at the wrist by deposits of GAGs, and/or Dupuytren's contractures affect hand movements, including the ability to grasp objects and to pinch. 7 In conjunction, these abnormalities contribute to a significant inability to perform simple acts necessary to daily life, such as feeding oneself, dressing and performing personal hygiene, and to accomplish practical tasks such as opening doors, answering telephones, catching the bus, etc. With relation to treatment, hematopoietic cell transplantation (HCT) is a strategy which risk/benefit is not well-established.
Enzyme replacement therapy (ERT) has shown itself to be a potential strategy for the treatament of some MPS, with encouraging results, but long-term follow-up is still needed.
11-14
The principal objective of this study was to describe the profile of the joint mobility, based on the assessment of specific joints (shoulders, elbows and knees), and to evaluate the grip and digit to digit and lateral pinch strength of a group of patients with MPS VI who had not previously been treated with ERT or HCT. The secondary objectives were to assess the correlations between mean joint mobility scores, grip strength and pinch strength and age, urinary GAG excretion, ARSB activity and performance in the 6-minute walking test (6MWT).
Methods

This study was approved by the National Research Ethics
Commitee (CONEP -Comissão National de Ética em Pesquisa) and meets all of the clinical research regulations, including the informed consent. In order to be included in the study, patients had to have a diagnosis of MPS VI confirmed 
Pinch strength assessment (digit to digit and lateral pinch)
A B&L Mechanical pinch dynamometer, scaled in pounds, was used to assess pinch strength of the 1st. and 2nd digits (digit to digit and lateral pinch). In order to take this measurement the elbow had to be at 90º, and the forearm and wrist in a neutral position. Three measurements were taken of each pinch strength and the mean of each taken. The results from the left and right sides were compared (Student's t test for paired samples) and, when there was no difference between them, their mean was taken.
Grip strength assessment (manual pressure)
A manual, hydraulic dynamometer, Jamar brand, was employed in this study to measure and grip strength, according to a standardized technique. Three measurements were 
Urinary GAG assays
Random urine samples were analysed, as described by Jong et al.
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Measurement of ARSB activity in leukocytes
It was performed as described by Kresse et al.
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Six-minute walking test (6MWT)
Performed according to the American Thoracic Society guidelines. 19 Two tests were performed on different days and the mean taken for analysis.
Results
Twenty-eight patients were enrolled on the study (males:
15; females: 13). None of the patients reported having received, during the year prior to the study, rehabilitation therapy on a regular basis (at least one session per week).
Mean age at assessment was 8. The correlations between these digit to digit and lateral pinch loss ratios and urinary GAG levels, ARSB activity and 6MWT performance were not significant.
No correlation was found between the JMA of the joints assessed and grip and pinch strength measurements, or between JMA and grip and pinch strength and urinary GAG excretion, enzyme activity (ARSB) and 6MWT performance.
Discussion
Studies of the mobility and strength profiles of MPS VI patients, and those with MPS in general, are scarce and those that do exist employ these variables as measures of treatment outcomes (ERT or HCT). 11, 13, 14, [22] [23] [24] Therefore, the information provided by this study is of relevance, especially to future studies that aim to assess the impact of specific treatments for MPS VI on the osteoarticular system. The fact that the grip strength of 23 of the 26 patients was zero reflects the major involvement of finger flexion that is associated with MPS VI. However, another possible cause could be the use of an inappropriate dynamometer which is unable to measure small displacements of the fingers. In contrast, the compromised finger joint mobility did not impede pinch movements, neither digit to digit nor lateral pinch, despite major deficits in strength and mobility, and there was a positive correlation between age and both digit to digit and lateral pinch strengths (strength was greatest in the oldest patients, despite being well below normal values). This, therefore, is one possible outcome that could be assessed in future research.
We believe studies that have the objective of delineating the natural history of MPS and which employ accessible methods that are reproducible and sensitive, such as the ones used in this study, should continue to be carried out . It is only thus that better markers, both of disease progression and for monitoring the effects of drug and rehabilitation treatments, can be defined.
